CHMP opinion is a step closer to the approval of an eight-week regimen of VIEKIRAX + EXVIERA for previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) patients with minimal to moderate fibrosis* AbbVie's EMA label expansion is supported by 98 percent SVR rate in patients in the dedicated Phase 3b GARNET study GT1b is the most common HCV subtype globally and accounts for approximately 47 percent of the estimated nine million people infected with chronic HCV in Europe Paritaprevir is Enanta's lead protease inhibitor and one of the three direct-acting antivirals in VIEKIRAX + EXVIERA WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 27, 2017-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA),...
↧